Skylark Bio Added Gene Therapy for Angelman Syndrome
The Cambridge-based company has expanded its development pipeline to include a new candidate for the rare genetic disorder.
Live Poll
Do you trust that pharmaceutical companies are sufficiently prioritizing the development of treatments for rare diseases?